A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine

• Change from baseline (premedicated) to 24 weeks in ADHD symptoms as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) total score. [ Time Frame: Baseline (premedicated) to 24 weeks post-treatment ]
• Change from baseline in academic performance of medication naive patients treated with atomoxetine at 24 weeks as measured by School Grade Average. [ Time Frame: Baseline (premedicated) and 16 - 24 weeks post-treatment ]

• Correlation Between Change From Baseline to 24 Week Endpoint in ADHDRS-IV-Parent:Inv Total Score and School Grade Averages in Separate Language, Math and Science Classes [ Time Frame: Baseline, 24 weeks ] [ Designated as safety issue: No ]
• Change From Baseline to 24 Week Endpoint in Academic Performance by School Grade Average (SGA) Total, and Separate Language, Math, and Science Scores [ Time Frame: Baseline, 24 weeks ] [ Designated as safety issue: No ]
• Change From Baseline to 24 Week Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored - Total Score [ Time Frame: Baseline, 24 weeks ] [ Designated as safety issue: No ]
• Change From Baseline to 24 Week Endpoint in Clinical Global Impressions - Attention-Deficit/Hyperactivity Disorder - Severity Scale (CGI-ADHD-S) [ Time Frame: Baseline, 24 weeks ] [ Designated as safety issue: No ]
• CGI-ADHD-Improvement Scale (CGI-ADHD-I) at 24 Week Endpoint [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
• Change From Baseline to 24 Week Endpoint in Revised Conners' Parent Rating Scale: Short Form (CPRS-R:S) Attention-Deficit/Hyperactivity Disorder Index Score [ Time Frame: Baseline, 24 weeks ] [ Designated as safety issue: No ]

• Change from baseline to 24 weeks in ADHD symptoms as measured by the total score of the Clinical Global Impressions - Attention-Deficit/Hyperactivity Disorder - Severity Scale (CGI-ADHD-S). [ Time Frame: Baseline (premedicated) to 24 weeks post-treatment ]
• Change in ADHD symptoms, as measured by the total score of the CGI-ADHD-Improvement Scale (CGI-ADHD-I) at 24 weeks. [ Time Frame: Baseline (premedicated) to 24 weeks post-treatment ]
• Change from baseline to 24 weeks in ADHD symptoms, as measured by the Revised Conners' Parent Rating Scale: Short Form (CPRS-R:S). [ Time Frame: Baseline (premedicated) to 24 weeks post-treatment ]

The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children treated with atomoxetine.

Inclusion Criteria:

• Male or female outpatients between 8 and 11 years of age at study entry
• Attention-Deficit/Hyperactivity Disorder (ADHD) meeting the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) disease diagnostic criteria
• Patients who have never received medications psychotropic medications specifically to treat ADHD, or if they have received medication, that the trial of the psychotropic medication(s) was of less than 1 month duration, and occurred more than 6 months prior to study entry
• Normal intelligence in the judgment of the investigator
• Must be able to swallow capsules

Exclusion Criteria:

• Current or past history of bipolar I or II disorder, psychosis, autism, Asperger's syndrome, pervasive developmental disorder, or conduct disorder
• History of seizure disorder or currently taking anticonvulsants for seizure control
• Serious suicidal risk as determined by investigator
• Cardiovascular disease; current or past history of hypertension
• Previous treatment with atomoxetine